MX2024006505A - Metodos para tratar la agitacion y otros sintomas conductuales asociados con la demencia. - Google Patents

Metodos para tratar la agitacion y otros sintomas conductuales asociados con la demencia.

Info

Publication number
MX2024006505A
MX2024006505A MX2024006505A MX2024006505A MX2024006505A MX 2024006505 A MX2024006505 A MX 2024006505A MX 2024006505 A MX2024006505 A MX 2024006505A MX 2024006505 A MX2024006505 A MX 2024006505A MX 2024006505 A MX2024006505 A MX 2024006505A
Authority
MX
Mexico
Prior art keywords
dementia
methods
symptoms associated
behavioral symptoms
agitation
Prior art date
Application number
MX2024006505A
Other languages
English (en)
Spanish (es)
Inventor
Sven Jacobson
Thomas Macallister
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of MX2024006505A publication Critical patent/MX2024006505A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024006505A 2021-11-29 2022-11-15 Metodos para tratar la agitacion y otros sintomas conductuales asociados con la demencia. MX2024006505A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163283696P 2021-11-29 2021-11-29
PCT/US2022/079861 WO2023097151A1 (en) 2021-11-29 2022-11-15 Methods of treating agitation and other dementia-associated behavioral symptoms

Publications (1)

Publication Number Publication Date
MX2024006505A true MX2024006505A (es) 2024-06-05

Family

ID=86540411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006505A MX2024006505A (es) 2021-11-29 2022-11-15 Metodos para tratar la agitacion y otros sintomas conductuales asociados con la demencia.

Country Status (7)

Country Link
US (2) US20240423998A1 (https=)
EP (1) EP4440566A4 (https=)
JP (1) JP2024544500A (https=)
CN (1) CN118354769A (https=)
CA (1) CA3236462A1 (https=)
MX (1) MX2024006505A (https=)
WO (1) WO2023097151A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
WO2025024104A2 (en) * 2023-07-06 2025-01-30 Woolsey Pharmaceuticals, Inc. Method for reducing caregiver burden associated with alzheimer's disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104340D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
WO2008019395A2 (en) 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
CN101612157A (zh) 2008-06-26 2009-12-30 天津红日药业股份有限公司 法舒地尔诱导成年脑内源性神经干细胞再生的用途
US9980972B2 (en) 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
WO2015070170A1 (en) * 2013-11-08 2015-05-14 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
US10537567B2 (en) * 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
WO2019018855A1 (en) * 2017-07-21 2019-01-24 Kadmon Corporation, Llc ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
EP3868408A4 (en) 2018-10-15 2022-07-06 National University Corporation Tokai National Higher Education and Research System Antipsychotic and use thereof
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
US11642352B2 (en) 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
CA3169944A1 (en) 2020-03-25 2021-09-30 Thomas Macallister Methods of using rho kinase inhibitors to treat frontotemporal dementia
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
CN116249532A (zh) 2020-06-15 2023-06-09 乌尔塞制药公司 使用Rho激酶抑制剂治疗血管性痴呆的方法
MX2022016336A (es) 2020-06-25 2023-01-24 Woolsey Pharmaceuticals Inc Metodos de tratamiento de trastornos del neurodesarrollo.
MX2023000600A (es) 2020-07-14 2023-02-13 Woolsey Pharmaceuticals Inc Metodos de tratamiento de proteinopatias.
EP4232041A4 (en) 2020-10-22 2024-09-25 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies
US20220331333A1 (en) 2021-04-16 2022-10-20 Universite De Strasbourg Rhoa pathway inhibitor in the treatment of neurodevelopmental disorder or neuropsychiatric disorder
WO2022245708A1 (en) 2021-05-19 2022-11-24 Woolsey Pharmaceuticals, Inc. Methods of treating depression and anxiety
MX2023013538A (es) 2021-05-19 2023-11-27 Woolsey Pharmaceuticals Inc Metodos para tratar la depresion y la ansiedad.

Also Published As

Publication number Publication date
JP2024544500A (ja) 2024-12-03
WO2023097151A1 (en) 2023-06-01
CN118354769A (zh) 2024-07-16
US20230201219A1 (en) 2023-06-29
US20240423998A1 (en) 2024-12-26
CA3236462A1 (en) 2023-06-01
EP4440566A1 (en) 2024-10-09
US11865119B2 (en) 2024-01-09
EP4440566A4 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
MX2024006505A (es) Metodos para tratar la agitacion y otros sintomas conductuales asociados con la demencia.
JOP20230277A1 (ar) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
UA102669C2 (xx) Застосування інгібіторів dpp iv$применение ингибиторов dpp iv
DE602005026054D1 (de) System zur überwachung oder behandlung von erkrankungen des nervensystems
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
DE69942702D1 (de) Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen
EP4288048A4 (en) OXA-IBOGAIN-INSPIRED ANALOGUES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
Jincai et al. Effects of vinpocetine and ozagrel on behavioral recovery of rats after global brain ischemia
EP3810142A4 (en) ANTIRETROVIRAL THERAPIES AND REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP4043075C0 (en) KN-93 INTENDED FOR USE IN THE PREVENTION AND TREATMENT OF PSORIASIS
EA202092557A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОБЕНЗОФУРО[2,3-c]ПИРИДИНА И БЕТА-КАРБОЛИНА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ-БЕЛКА
Park et al. Effects of Acupuncture on Alzheimer’s Disease in Animal‐Based Research
EP4288075A4 (en) SELECTIVE INHIBITION OF ROCK2 FOR THE TREATMENT OF EDEMA AND RELATED CONDITIONS
EP4251753A4 (en) TREATMENT OF DISEASES AND DISORDERS RELATED TO SOS2
MX2019006141A (es) Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.
BR112019024878A2 (pt) Agente para prevenção ou tratamento de tauopatia
Lalegani et al. The effects of breathing techniques on pain intensity of burn dressing-A clinical randomized trial
JP2020504719A5 (https=)
EP4561695A4 (en) PHOTOTHERAPY DEVICE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MX2022010456A (es) Compuestos heterocíclicos para modular la subfamilia de receptores nucleares 2, grupo f, miembro 6.
BRPI0309594A8 (pt) Piperazina benzothiazóis como agentes para o tratamento de distúrbios isquêmicos cerebrais ou distúrbios do snc
EP4355430A4 (en) TREATMENT OF DISEASES AND DISORDERS RELATED TO MST1R
Stanton The Chinese Ear Shenmen Point and the French Cosmonaut Point: Same or Different?
MX2022014356A (es) Ciertas composiciones quimicas y metodos de uso de las mismas.